NGM Biopharmaceuticals/NGM

$1.52

0%
-
1D1W1MYTD1YMAX

About NGM Biopharmaceuticals

NGM Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel, potentially life-changing medicines based on scientific understanding of key biological pathways underlying grievous diseases with critical unmet or underserved patient need. The Company’s portfolio of product candidates includes NGM707, NGM831, NGM438, NGM120, NGM621, aldafermin, NGM936 and MK-3655. NGM707 is a dual antagonist monoclonal antibody that is designed to improve patient immune responses to tumors by inhibiting both Immunoglobulin-like transcript 2 (ILT2) and Immunoglobulin-like transcript 4 (ILT4). The Company's NGM831 is an antagonist antibody that is designed to block the interaction of Immunoglobulin-like transcript 3 (ILT3) with fibronectin, as well as other cognate ligands. NGM438 is an antagonist antibody that is designed to inhibit leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) and promote anti-tumor immune responses.

Ticker

NGM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

William Rieflin

Employees

239

Headquarters

South san francisco, United States

NGM Metrics

BasicAdvanced
$126.86M
Market cap
-
P/E ratio
-$1.84
EPS
1.26
Beta
-
Dividend rate

What the Analysts think about NGM

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 5 analysts.
66.45% upside
High $6.00
Low $1.55
$1.52
Current price
$2.53
Average price target

NGM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-5,740% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$500K
-64.29%
Net income
$-28.7M
-24.87%
Profit margin
-5,740%
110.37%

NGM Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 17.52%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.45
-$0.58
-$0.46
-$0.35
-
Expected
-$0.52
-$0.52
-$0.50
-$0.42
-$0.39
Surprise
-12.62%
12.15%
-7.6%
-17.52%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell NGM Biopharmaceuticals stock

Buy or sell NGM Biopharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing